ABBV-1042

Small molecule

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity
NCT07222709 · AbbVie
2025-10-27 – 2026-09-18 · Healthy Volunteer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for Bipolar Disorder: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ABBV-1042: this drugStage not on recordSmall moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Direclidine
Phase 3(overall)
Small moleculeMuscarinic M4 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
Emraclidine
Phase 2(overall)
Small moleculeMuscarinic M4 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
NTX-253
Phase 1(overall)
Small moleculeMuscarinic M4 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.